Anne-Virginie Eggimann joined Tessera in 2022 after leading the Regulatory Science function for nearly 11 years, most recently as Chief Regulatory Officer, at bluebird bio, Inc. She oversees several key functions responsible for driving forward the development of the company genome engineering products, including Regulatory Science, Program, Portfolio & Alliance Management, Program Leadership and Medical and Technical Writing. She is also responsible for Tessera’s Regulatory Intelligence & Policy activities. During her tenure at bluebird bio, she played a key role in partnering with regulators to bring the company’s pioneering gene therapy products in severe genetic diseases and oncology from preclinical development to registration, leading to several recent approvals in Europe and the United States for Zynteglo and Skysona, as well as Abecma in partnership with Bristol Myers Squibb. Prior to joining bluebird, Anne-Virginie was an Executive Director at Voisin Consulting Life Sciences. She currently serves on the board of Codiak Biosciences and holds a Master of Science from the UCLA School of Public Health, and a B.S. in Chemical Engineering from the California Institute of Technology.